CombiGene: Now we’re strengthening our management team with the addition of Karin Agerman as Chief Research & Development Officer.

During 2018 CombiGene is entering a decisive phase with focus on development of a manufacturing method for our candidate drug, CG01, and continued intensive business development. This will demand a good measure of professionalism and expertise, as well as energy and enthusiasm.

Read more >> –>